NEUROGENE INC
NGNENASDAQ🏆 #2510 by market capEarnings Nov 12US Equity
$36.28▲ $0.49 (+1.34%)
Live1h▼ 1.6%
24h▲ 1.3%
7d▲ 0.6%
14d▲ 8.0%
30d▼ 5.1%
1y▲ 89.4%
🏦Market Cap
$573M
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
55
Weak
Trading Snapshot
- Day Range
- $35.96 – $36.74
- 52-Week Range
- $15.93 – $43.66
- Volume
- $2.63B
- Avg Volume
- $3.10B
- Shares Outstanding
- 15.8M
- Next Earnings
- Sep 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $140M
- Last Q Revenue
- $34M
- P/E Ratio
- -6.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-4.93
- Dividend Yield
- 0.00%
Why Investors Own NGNE
- ✓High-growth profile — revenue up +38.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 48% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$140M▲ +35.4% YoY
Gross Margin (TTM)
47.5%▲ +1.7% YoY
Operating Income (TTM)
$16M▲ +35.4% YoY
Free Cash Flow (TTM)
$16M▲ +35.4% YoY
About NEUROGENE INC
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
55/100
Analyst Ratings
ⓘConsensus
Buy
15 analysts
Strong Buy6
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026